Selecting the optimal targeted therapy for relapsed B-acute lymphoblastic leukemia.

Despite an initial 80–90% response rate to therapy, approximately 50% of adult patients with B-acute lymphoblastic leukemia (B-ALL) subsequently relapse. Historically allogeneic hematopoietic stem ...